<DOC>
	<DOCNO>NCT02621528</DOCNO>
	<brief_summary>The purpose multi-center , interventional , prospective , post-market study collect real world data patient outcomes evaluate procedural success performance Lifetech CeraFlex™ occluders patient secundum type Atrial Septum Defect ( ASD ) , Patent Foramen Ovale ( PFO ) Patent Ductus Arteriosus ( PDA ) .</brief_summary>
	<brief_title>Lifetech CeraFlex™ Post-Market Surveillance Study</brief_title>
	<detailed_description>The Lifetech CeraFlex device CE mark shall use study within intend use describe approved corresponding Instructions For Use ( IFU ) . Approximately 120 patient include study . The patient population consist 40 consecutive patient confirm secundum type ASD , 40 patient PFO 40 patient PDA result significant shunt require intervention . This study conduct 12 investigational center locate Europe Middle East . Subjects follow 12 month post-procedure , follow-ups per local hospital standard expect discharge , 1 3 month , 6 month 12 month .</detailed_description>
	<mesh_term>Ductus Arteriosus , Patent</mesh_term>
	<mesh_term>Foramen Ovale , Patent</mesh_term>
	<mesh_term>Heart Septal Defects</mesh_term>
	<mesh_term>Heart Septal Defects , Atrial</mesh_term>
	<criteria>To participate study , patient must meet follow inclusion criterion : 1 . Confirmed ASD , PFO PDA patient characteristic consistent correspond IFU size guideline ; 2 . The patient legally authorize representative inform nature study , agree provision provide write informed consent , approve appropriate Ethics Committee ( EC ) ; 3 . The patient agree comply requirement study include 12 month followup . Patients exclude follow condition apply : 1 . Any contraindication mention correspond IFU ; 2 . Currently participate investigational drug device study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CeraFlex occluder</keyword>
</DOC>